Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Characterizing the immune microenvironment before and following anti-HER2 neoadjuvant therapy

Gaia Griguolo • 12 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Lapatinib Trastuzumab
PAMELA

Gaia Griguolo, MD, of the Istituto Oncologico Veneto, Padua, Italy, characterizes the immune microenvironment of early HER2+ breast cancer before and after treatment with lapatinib and trastuzumab without chemotherapy in the context of the PAMELA trial (NCT01973660), and its relationship with intrinsic subtyping and pathologic complete response (pCR). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Gaia Griguolo

2:09
HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BC
Gaia Griguolo • 7 Dec 2022
0:53
The latest news on the management of breast cancer patients with brain metastases
Gaia Griguolo • 7 Dec 2022
1:35
Gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes
Gaia Griguolo • 7 Dec 2022
1:19
Gene expression assays to identify patients with breast cancer for neoadjuvant treatment
Gaia Griguolo • 3 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals